Company profile

Ticker
IMMU
Exchange
CEO
Harout Semerjian
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
611009366

IMMU stock data

(
)

Calendar

6 May 20
7 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue NaN 295K NaN NaN
Net income -93.08M -99.64M -94.32M -75.95M
Diluted EPS -0.44 -0.5 -0.49 -0.4
Net profit margin NaN% -33776% NaN% NaN%
Operating income -81.97M -91.25M -86.77M -67.17M
Net change in cash -72.33M 243.97M -63.26M -10.03M
Cash on hand 536.3M 608.63M 364.65M 427.91M
Cost of revenue NaN NaN NaN

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
18 Jun 20 Azelby Robert Common Stock, $0.01 par value per share Grant Aquire A No 0 3,718 0 3,718
18 Jun 20 Azelby Robert Stock Option Common Stock, par value $0.01 per share Grant Aquire A No 33.62 6,540 219.87K 6,540
18 Jun 20 Charles M Baum Common Stock, $0.01 par value per share Grant Aquire A No 0 3,718 0 13,385
18 Jun 20 Charles M Baum Stock Option Common Stock, par value $0.01 per share Grant Aquire A No 33.62 6,540 219.87K 6,540
18 Jun 20 Hutt Peter Barton Common Stock, $0.01 par value per share Grant Aquire A No 0 3,718 0 17,234
18 Jun 20 Hutt Peter Barton Stock Option Common Stock, par value $0.01 per share Grant Aquire A No 33.62 6,540 219.87K 6,540
18 Jun 20 Islam Khalid Common Stock, $0.01 par value per share Grant Aquire A No 0 3,718 0 17,234
18 Jun 20 Islam Khalid Stock Option Common Stock, par value $0.01 per share Grant Aquire A No 33.62 6,540 219.87K 6,540
18 Jun 20 Duncan Barbara Gayle Common Stock, $0.01 par value per share Grant Aquire A No 0 3,718 0 13,385
18 Jun 20 Duncan Barbara Gayle Stock Option Common Stock, par value $0.01 per share Grant Aquire A No 33.62 6,540 219.87K 6,540
76.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 223 251 -11.2%
Opened positions 33 66 -50.0%
Closed positions 61 25 +144.0%
Increased positions 80 82 -2.4%
Reduced positions 63 63
13F shares
Current Prev Q Change
Total value 11.28B 18.59B -39.3%
Total shares 176.82M 172.52M +2.5%
Total puts 940.16K 1.56M -39.9%
Total calls 1.93M 3.59M -46.3%
Total put/call ratio 0.5 0.4 +11.9%
Largest owners
Shares Value Change
Avoro Capital Advisors 24.5M $330.26M 0.0%
Vanguard 16.85M $227.14M +3.5%
BLK BlackRock 15.78M $212.69M +7.4%
Boxer Capital 8.45M $113.91M 0.0%
STT State Street 7.08M $95.38M +4.3%
Palo Alto Investors 5.29M $71.32M -10.7%
ArrowMark Colorado 5.25M $70.73M -2.7%
AMP Ameriprise Financial 5.2M $70.04M +19.6%
Jennison Associates 5.02M $67.69M +66.1%
N Price T Rowe Associates 4.93M $66.44M -15.4%
Largest transactions
Shares Bought/sold Change
Point72 Asset Management 3.5M +3.5M NEW
Citadel Advisors 2.77M +2.53M +1040.8%
Deerfield Management 4.11M +2.38M +138.4%
Jennison Associates 5.02M +2M +66.1%
Norges Bank 0 -1.78M EXIT
Woodline Partners 1.94M +1.37M +237.6%
Foresite Capital Management III 400K -1.35M -77.1%
JHG Janus Henderson 2.61M -1.1M -29.6%
BLK BlackRock 15.78M +1.08M +7.4%
Panagora Asset Management 290K -1M -77.6%

Financial report summary

?
Risks
  • The outbreak of the SARS-CoV-2 virus and the COVID-19 disease that it causes , or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including clinical development of our product candidates, manufacturing, commercial operations and sales.
  • We have a long history of operating losses and it is likely that our operating expenses will continue to exceed our revenues for the foreseeable future.
  • We have significant future capital needs and may be unable to raise capital when needed, which could force us to delay or reduce our clinical development efforts.
  • Although we received accelerated approval of our BLA for Trodelvy for patients with metastatic triple-negative breast cancer, our other most advanced therapeutic product candidates are still only in the clinical development stage, and may require us to raise capital in the future in order to fund further expensive and time-consuming studies before they can even be submitted for final regulatory approval. A failure of a clinical trial could severely harm our business and results of operations.
  • Our clinical trials may not adequately show that our drugs are safe or effective, and a failure to achieve the planned endpoints could result in termination of product development or a withdrawal of our accelerated approval for Trodelvy.
  • Information obtained from our Expanded Access Program launched in January 2020 may not reliably predict the efficacy of our product candidates in company-sponsored clinical trials and may lead to adverse events that could limit approval.
  • Should the clinical development process be successfully completed, our ability to derive revenues from the sale of therapeutics will depend upon our first obtaining FDA as well as foreign regulatory approvals, all of which are subject to a number of unique risks and uncertainties.
  • In order to fund future operations, we will need to raise significant amounts of additional capital. Because it can be difficult for a mid-cap company like ours to raise equity capital on acceptable terms, we cannot assure you that we will be able to obtain the necessary capital when we need it, or on acceptable terms, if at all.
  • If we, or any of our collaboration partners, or our or their contract manufacturers, cannot successfully and efficiently manufacture the compounds that make up our products and product candidates, our ability, and the ability of our collaboration partners, to sell products and conduct clinical trials will be impaired.
  • Although historically we have been a research and development company, we are commercializing our lead product internally rather than licensing such asset. There can be no assurance that we will be successful in developing and expanding commercial operations or balancing our research and development activities with our commercialization activities.
  • We may not successfully establish and maintain collaborative and licensing arrangements, which could adversely affect our ability to develop and commercialize certain of our product and product candidates. Any of our collaboration partners may not adequately perform their responsibilities under our agreements, which could adversely affect our development and commercialization program.
  • Our future success will depend upon our ability to first obtain and then adequately protect our patent and other intellectual property rights, as well as avoiding the infringement of the rights of others.
  • Expiry of our intellectual property rights could lead to increased competition.
  • We face substantial competition in the biotechnology industry and may not be able to compete successfully against one or more of our competitors.
  • We may be liable for contamination or other harm caused by hazardous materials that we use in the operations of our business.
  • The nature of our business exposes us to significant liability claims, and our insurance coverage may not be adequate to cover any future claims.
  • Certain potential for conflicts of interest, both real and perceived, exist which could result in expensive and time-consuming litigation.
  • The commercial success of our product and product candidates depends on the availability and sufficiency of third-party payor coverage and reimbursement. Given that recent cancer therapeutics for solid cancers such as the ones we are developing can cost approximately in the range of $13,000 to $30,000 a month, even if our product candidates become available for sale it is likely that federal and state governments, insurance companies and other payors of health care costs will try to first limit the use of these drugs to certain patients, and may be reluctant to provide a level of reimbursement that permits us to earn a significant profit on our investment, if any.
  • A portion of our funding has come from federal government grants and research contracts. Due to reductions in funding, we may not be able to rely on these grants or contracts as a continuing source of funds.
  • We face a number of risks relating to the maintenance of our information systems and our use of information relating to clinical trials.
  • Legislative or regulatory reform of the healthcare system may affect our ability to sell our products profitably.
  • Healthcare laws and regulations may affect the pricing of our product and product candidates and may affect our profitability.
  • Our industry and we are subject to intense regulation from the United States Government and other governments and quasi-official authorities regulating where our products are and product candidates may be sold.
  • Our failure to comply with foreign data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.
  • Our employees and our independent contractors, principal investigators, consultants or commercial collaborators, as well as their respective sub-contractors, if any, may engage in misconduct or fail to comply with certain regulatory standards and requirements, which could expose us to liability and adversely affect our reputation.
  • Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Our indebtedness and debt service obligations may adversely affect our cash flow.
  • We may add lease lines to finance capital expenditures and may obtain additional long‑term debt and lines of credit. If we issue other debt securities in the future, our debt service obligations will increase further.
  • Shares eligible for future sale may adversely affect our ability to sell equity securities.
  • Our outstanding options may adversely affect our ability to consummate future equity‑based financings due to the dilution potential to future investors.
  • The market price of our common stock has fluctuated widely in the past, and is likely to continue to fluctuate widely based on a number of factors, many of which are beyond our control.
  • Our principal stockholder can significantly influence all matters requiring the approval by our stockholders.
  • There are limitations on the liability of our directors, and we may have to indemnify our officers and directors in certain instances.
  • We are exposed to potential risks from legislation requiring companies to evaluate controls under Section 404 of the Sarbanes-Oxley Act.
  • We do not intend to pay dividends on our common stock. Until such time as we pay cash dividends, our stockholders, must rely on increases in our stock price for appreciation.
Management Discussion
  • Our results for any interim period, such as those described in the following analysis, are not necessarily indicative of the results for the entire year or any other future period.
  • Total costs and expenses for the three months ended March 31, 2020 increased $2.3 million compared to the three months ended March 31, 2019, primarily due to an increase in research and development expenses of $4.3 million, and an increase in sales and marketing expenses of $0.2 million, partially offset by a decrease in general and administrative expenses of $2.1 million.
  • We do not track expenses on the basis of each individual compound under investigation and therefore we do not provide a breakdown of such historical information in that format. We evaluate projects under development from an operational perspective, including such factors as results of individual compounds from laboratory/animal testing, patient results and enrollment statistics in clinical trials. It is important to note that multiple product candidates are often tested simultaneously. It is not possible to calculate each antibody’s supply costs. There are many different development processes and test methods that examine multiple product candidates at the same time. We have, historically, tracked our costs in the categories discussed below, specifically “research costs” and “product development costs” and by the types of costs outlined below.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: AbbVie, adherence, aggressive, aimed, analyze, androgen, anecdotal, ASCENT, aspect, assist, assistance, Azar, ban, beneficiary, biosimilar, Brigham, California, CancerCare, CCPA, CEO, codified, comparison, compelling, compliant, component, context, Corrupt, Dana, defect, disrupt, disrupted, disruption, domestic, DSCSA, economy, elongation, employ, endometrial, eventual, evidence, evolved, Farber, Fast, faster, focusing, front, geographic, German, group, guarantee, Harout, heard, higher, House, ineligible, inflationary, instance, instrument, interface, introduced, master, Matthey, meaningfully, median, MGH, MGM, mission, mNSCLC, moved, MSA, mUC, multicenter, NeoSTAR, onset, open, opportunity, opt, outbreak, pace, pandemic, pathway, PBM, PDMA, pedigree, percent, persistent, PhRMA, physical, pivotal, platform, platinum, point, poly, polymerase, postmarketing, preapproval, predominantly, prioritization, profile, push, quarantine, RECIST, recurrent, regimen, remanded, remote, removing, rendered, respiratory, rest, Rubraca, rucaparib, sample, Samsung, Sanofi, Semerjian, Senate, simplify, Simplifying, situation, slower, spread, statue, stringent, TALZENNA, temporarily, tracing, transform, travel, Trodelvy, unblinding, unclear, uncontrolled, usage, variable, vendor, verification, verify, White, withdrawn, Women, workforce, world, Wuhan, Yale
Removed: acceleration, Acquisition, advertisement, allegation, Amgen, approach, arm, arrange, assert, Bayer, borrow, borrowing, Celgene, cell, cessation, cGCP, classification, commencing, communication, comprised, constitute, consultant, Council, covenant, creation, CRL, dealing, derived, Dhingra, dilute, discontinued, disposition, dispute, dissolution, earliest, earned, EIR, Eli, enclosing, engineering, Establishment, estate, exercised, existence, expedited, expired, feedback, forfeited, fundamental, Genmab, govitecan, grace, impacting, incremental, indenture, investigator, issuable, jeopardized, Kapil, Kapital, labetuzumab, leasing, LeukoScan, Lilly, liquidation, listing, lung, mature, maturity, MedImmune, memorialize, modified, modify, monoclonal, MRC, negotiate, nonemployee, notified, NQSO, opposition, optional, original, par, payable, PDUFA, practical, prepayment, prevailing, proceed, professional, promising, proposal, rejection, replacement, represent, repurchase, retrospective, Revised, revocation, semiannually, Serono, sharing, site, stated, stayed, step, strike, surrendered, television, twelve, unit, unpaid, unsecured, utility, utilize, warrant, York